Understanding Parkinson’s Progression and Latest Research Breakthroughs

Welcome to episode seven of The Caring Neurologist, where hosts Dr. Sandeep Thakkar dives deep into the world of Parkinson’s disease, this time shining a spotlight on the cutting edge of clinical research. In this episode, Dr. Thakkar explains why research and care are inseparable for truly advancing Parkinson’s treatment, and opens up about the most exciting developments shaping the field today. From discussing the importance and process of clinical trials, to breaking down how gene therapy, artificial intelligence, and novel therapies like stem cells are transforming what’s possible for Parkinson’s patients, this conversation is packed with hope and real-world insights. Dr. Thakkar shares his unique perspective as both a hands-on physician and research leader, offering a glimpse into promising new studies and explaining how patients can get involved in shaping the future of care. If you or a loved one are navigating Parkinson’s or just curious about how research becomes real-life treatment breakthroughs, this episode is filled with practical wisdom, encouragement, and a peek at the innovations on the horizon. So grab your notebook and get ready to be inspired by Dr. Thakkar’s passion and expertise, as he remind us why curiosity, partnership, and patient empowerment are the driving forces behind progress. Timestamps: 00:00 FDA Clinical Trial Phases 07:20 Advancements in Parkinson's Research 09:49 AI in Pharma: Molecular Insights 12:48 Parkinson's Research Developments 17:50 Parkinson’s as a Proteinopathy 20:53 Clinical Trial Participation Considerations 25:55 Pharma Influence on Politics 29:46 Parkinson’s Care and Research Hub 32:05 Purpose-Driven Career 34:16 Recording End Acknowledgment Quotes, Hooks & Timestamps: "And within the clinical trials there'll be a phase one trial which involves usually 20 to 100 people monitoring safety of a Medication and a dosage. And then a phase two trial will then have certain guidelines of less than 100 people, typically where you're continuing to test for safety as well as effectiveness. And then we get into the phase three trials when we have a large group of participants that will confirm the efficacy of the therapy that's being offered." — Dr. Sandeep Thakkar [00:03:10 → 00:03:42] "People can manage their disease, they can still live their life well, they can still work and enjoy travel." — Dr. Sandeep Thakkar [00:06:16 → 00:06:22] "But pharmaceutical companies, the government are working with certain types of programs that we can even understand the molecular structure of a medication and understand how it can actually fit into receptors of the brain. It can model what the receptors are abnormal or the enzymes in the brain that are abnormal with Parkinson's, and then see if it can create medications that would also fit into those structures." — Dr. Sandeep Thakkar [00:09:57 → 00:10:26] "And it's using human embryonic stem cells that will mature into the dopamine cells for the brain of Parkinson's. And we can implant those to see if that's going to make a difference in the motor outcomes and help restore areas that have been affected or destroyed by Parkinson's disease." — Dr. Sandeep Thakkar [00:12:18 → 00:12:36] So we may have even cures for patients in the coming years. That's, I think, gonna be the most phenomen, phenomenal aspect at this time. — Dr. Sandeep Thakkar [00:13:56 → 00:14:04] "Parkinson's is a slow version of mad cow disease." — Dr. Sandeep Thakkar [00:18:35 → 00:18:38] "I mean, if you think about it, who puts our politicians in office, it's the pharma companies. So I think that the insurance companies do the same thing. And all of these big businesses have influence and money brings in these politicians that make the rules that they themselves may not follow." — Dr. Sandeep Thakkar [00:26:18 → 00:26:36] "And so what I have the opportunity is to bridge patient care with something that is evidence based. And we're providing information, we're providing therapies, and I get a partnership that I wouldn't be able to utilize to help those that come into our office." — Dr. Sandeep Thakkar [00:27:47 → 00:28:04] "Well, we're, you know, 99% of our practice is Parkinson's and essential tremors and other movement disorders. So we are, in fact, a big hub where centers want to come. We actually have a higher patient volume than most universities, even in our area." — Dr. Sandeep Thakkar [00:30:07 → 00:30:25] The Caring Neurologist - Podcast Website - https://thecaringneurologist.com/ Dr. Sandeep Thakkar - LinkedIn -   / sandeep-thakkar-do-798a2499   Dr. Sandeep Thakkar - Clinic - https://ocparkinsons.com/about-mdpds/... TopHealth - https://tophealth.care/